Citigroup Upgrades Hims & Hers Health to Neutral, Raises Price Target to $24
Hims & Hers Health
Hims & Hers Health HIMS | 0.00 |
Citigroup analyst Daniel Grosslight upgrades Hims & Hers Health (NYSE:
HIMS) from Sell to Neutral and raises the price target from $13.25 to $24.
